Literature DB >> 16473336

Long-term memory for aversive training is impaired in Idua(-/-) mice, a genetic model of mucopolysaccharidosis type I.

Gustavo Kellermann Reolon1, Luisa Macedo Braga, Melissa Camassola, Tatiana Luft, João Antônio Pêgas Henriques, Nance Beyer Nardi, Rafael Roesler.   

Abstract

Mucopolysaccharidosis type I (MPS I) is a lysosomal storage disease that leads to neurodegeneration and neurological deficits, among other pathological and clinical consequences. The aim of the present study was to evaluate neurobehavioral parameters in a genetic mouse model of mucopolysaccharidosis type I (MPS I). During exploration of an open field, adult MPS I (Idua(-/-)) mice showed normal locomotion and anxiety but reduced number of rearings. Idua(-/-) mice performed normally in a novel object recognition memory task and showed normal short-term retention of inhibitory avoidance training. By contrast, long-term retention of inhibitory avoidance was impaired in Idua(-/-) mice. The deficit in inhibitory avoidance memory could not be attributed to reduced footshock reactivity. The results indicate that Idua(-/-) mice present deficits in long-term memory for aversive training and reduced exploratory behavior.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16473336     DOI: 10.1016/j.brainres.2006.01.008

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  14 in total

1.  Proteomic analysis of mucopolysaccharidosis I mouse brain with two-dimensional polyacrylamide gel electrophoresis.

Authors:  Li Ou; Michael J Przybilla; Chester B Whitley
Journal:  Mol Genet Metab       Date:  2016-10-11       Impact factor: 4.797

Review 2.  Lysosomal storage disease: gene therapy on both sides of the blood-brain barrier.

Authors:  Elena L Aronovich; Perry B Hackett
Journal:  Mol Genet Metab       Date:  2014-10-07       Impact factor: 4.797

3.  Characterization of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human stem cell and gene therapy.

Authors:  Mayra F Garcia-Rivera; Leah E Colvin-Wanshura; Matthew S Nelson; Zhenhong Nan; Shaukat A Khan; Tyson B Rogers; Indrani Maitra; Walter C Low; Pankaj Gupta
Journal:  Brain Res Bull       Date:  2007-08-06       Impact factor: 4.077

4.  Progression of multiple behavioral deficits with various ages of onset in a murine model of Hurler syndrome.

Authors:  Dao Pan; Anthony Sciascia; Charles V Vorhees; Michael T Williams
Journal:  Brain Res       Date:  2007-10-23       Impact factor: 3.252

5.  Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation.

Authors:  Dan Wang; Charu Shukla; Xiaoli Liu; Trenton R Schoeb; Lorne A Clarke; David M Bedwell; Kim M Keeling
Journal:  Mol Genet Metab       Date:  2010-01       Impact factor: 4.797

6.  Retroviral-vector-mediated gene therapy to mucopolysaccharidosis I mice improves sensorimotor impairments and other behavioral deficits.

Authors:  Guilherme Baldo; David F Wozniak; Kevin K Ohlemiller; Yanming Zhang; Roberto Giugliani; Katherine P Ponder
Journal:  J Inherit Metab Dis       Date:  2012-09-15       Impact factor: 4.982

7.  Alterations in oxidative markers in the cerebellum and peripheral organs in MPS I mice.

Authors:  Gustavo Kellermann Reolon; Adalisa Reinke; Marcos Roberto de Oliveira; Luisa Macedo Braga; Melissa Camassola; Michael Everton Andrades; José Cláudio Fonseca Moreira; Nance Beyer Nardi; Rafael Roesler; Felipe Dal-Pizzol
Journal:  Cell Mol Neurobiol       Date:  2008-12-25       Impact factor: 5.046

8.  Evidence of a progressive motor dysfunction in Mucopolysaccharidosis type I mice.

Authors:  Guilherme Baldo; Fabiana Quoos Mayer; Barbara Martinelli; Anna Dilda; Fabiola Meyer; Katherine P Ponder; Roberto Giugliani; Ursula Matte
Journal:  Behav Brain Res       Date:  2012-05-09       Impact factor: 3.332

9.  A novel, long-lived, and highly engraftable immunodeficient mouse model of mucopolysaccharidosis type I.

Authors:  Daniel C Mendez; Alexander E Stover; Anthony D Rangel; David J Brick; Hubert E Nethercott; Marissa A Torres; Omar Khalid; Andrew Ms Wong; Jonathan D Cooper; James V Jester; Edwin S Monuki; Cian McGuire; Steven Q Le; Shih-Hsin Kan; Patricia I Dickson; Philip H Schwartz
Journal:  Mol Ther Methods Clin Dev       Date:  2015-02-11       Impact factor: 6.698

10.  A Valepotriate Fraction of Valeriana glechomifolia Shows Sedative and Anxiolytic Properties and Impairs Recognition But Not Aversive Memory in Mice.

Authors:  Natasha Maurmann; Gustavo Kellermann Reolon; Sandra Beatriz Rech; Arthur Germano Fett-Neto; Rafael Roesler
Journal:  Evid Based Complement Alternat Med       Date:  2011-01-12       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.